Perlmutter Cancer Center

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

• Conditions:
  Prostate Cancer
  Prostate
• Age: Between 18 Year(s) - 99 Year(s)
• Gender: Male

• Other Inclusion Criteria:
  

  1. Advanced (including locally) or metastatic solid tumors that are not eligible for curative therapy, with any homologous recombination (HR)-deficient alteration, and who are PARP inhibitor exposed
  2. Advanced (including locally) or metastatic solid tumors that are not eligible for curative therapy, for which a PARP inhibitor is indicated, with alterations in BRCA1, BRCA2, CDK12, PALB2, and/or RAD51B/C/D
  3. Metastatic castrationresistant prostate cancer (mCRPC), metastatic breast cancer (mBC), or metastatic pancreatic ductal adenocarcinoma (mPDAC), for which a PARP inhibitor is indicated, with alterations in BRCA2, PALB2, and/or RAD51B/C/D

  
  

You may not be eligible for this study if the following are true:

• 1. Participant has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study or interfere with the participant’s participation for the full duration of the study
  2. Participant has a known active infection. Participant is permitted to enroll once any required antibiotic, antifungal, and/or antiviral therapy has been completed and/or infection is determined to be controlled
  3. Participant has any known evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension, active bleeding diatheses, or other comorbidity that renders the participant unsuitable for participation in the study